Skip to main content
ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
4.875
-0.475 (-8.88%)
At close: Nov 20, 2024, 4:00 PM
4.850
-0.025 (-0.51%)
Pre-market: Nov 21, 2024, 7:42 AM EST

ImmunityBio Revenue

ImmunityBio had revenue of $6.11M in the quarter ending September 30, 2024, with 7,346.34% growth. This brings the company's revenue in the last twelve months to $7.33M, up 1,218.71% year-over-year. In the year 2023, ImmunityBio had annual revenue of $622.00K with 159.17% growth.

Revenue (ttm)
$7.33M
Revenue Growth
+1,218.71%
P/S Ratio
n/a
Revenue / Employee
$11,675
Employees
628
Market Cap
3.40B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023622.00K382.00K159.17%
Dec 31, 2022240.00K-694.00K-74.30%
Dec 31, 2021934.00K329.00K54.38%
Dec 31, 2020605.00K-1.60M-72.52%
Dec 31, 20192.20M-955.00K-30.25%
Dec 31, 2018 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
BrightSpring Health Services 10.59B
Acadia Healthcare Company 3.12B
Envista Holdings 2.50B
Neogen 912.20M
PTC Therapeutics 900.66M
Apellis Pharmaceuticals 715.22M
Rhythm Pharmaceuticals 112.53M
Verona Pharma 5.62M
Revenue Rankings

IBRX News

More News